Neuronostics has successfully secured £300K for the ongoing development of its revolutionary clinical decision support systems. The technology is built upon mathematical modelling and advanced AI tools that interrogate routinely acquired clinical data to reveal the risk of future seizures. Professor John Terry, Co-Founder and Managing Director, said “Securing this seed fund investment is incredibly exciting for the future development of Neuronostics. "To be able to announce this investment on Purple Day – the international day of awareness for epilepsy – is doubly exciting, as our products have the potential to bring many benefits to the millions of people globally impacted by epilepsy.” Richard Haycock, Co-Founder of QantX Ventures and who will join the board of Neuronostics, said “We are excited to become part of the Neuronostics journey, they have pioneered innovative technology that will make a significant positive difference to the lives of many people around the world.” Dr Neil Hayes, Assistant Director, Enterprise & Innovation Programmes at the University of Exeter, said “This investment represents another significant milestone for Neuronostics and will help bring the technology a step closer to bringing real benefit to people living with epilepsy. "The University of Exeter is pleased to be working with Neuronostics and QantX Ventures to deliver meaningful impact from our world leading research."